MTNR1B and anxiety disorder: A novel selective MT2 agonist also has anxiolytic properties (Ochoa-Sanchez et al., 2012), so our data reinforce the concept that MT2 receptors modulate anxiety responses, and that activation of MT2 receptors may have therapeutic potential in anxiety disorders.